International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 2, Issue 18 | Case Series | Open Access DOI
Anusmriti Pal*
Anusmriti Pal1*, Anand K Mishra2, Manoj K Yadav3, Rajendra Mani Giri2 and Khadga B Shah4
1Pulmonologist and Critical Care Specialist. Karnali Academy of Health Sciences
2Department of Internal Medicine. Karnali Academy of Health Sciences, Jumla, Nepal
3Consultant Pulmonologist and Critical Care Specialist. Nepal Police Hospital, Nepal
4Manager. Nepal Tourism Board, Kathmandu, Nepal
*Correspondence to: Anusmriti Pal
Fulltext PDFIntroduction:The purpose of this study was to determine the effect of nintedanib among critically ill COVID-19 patients and to assess its effect on their clinical status and radiological resolution from post-COVID pulmonary fibrosis. Antifibrotic drugs, such as Nintedanib, have emerged as an early treatment option for prevention and during post-COVID-19 pulmonary fibrosis which has been seen as early as 3 Weeks.
Case Presentation:A total of 4 critically ill COVID-19 patients confirmed by reverse transcriptase polymerase chain reaction were prescribed Nintedanib 4 weeks after intensive care unit (ICU) admission, at the dose of Idiopathic Pulmonary fibrosis (IPF). The dose was started from 100 mg BD for 10 days and then increased to 150 mg BD as tolerated by the patient. One patient lost follow-up on discharge, and another patient's drug had to be stopped in between due to adverse effects. So, two patients regularly followed for 1, 3, and 6 months after discharge and even after the stoppage of drugs. Over the period they showed drastic improvement in oxygen requirements, resting oxygen saturation, and symptoms such as cough and dyspnea. Serial high-resolution computed tomography (HRCT) chest scans and lung function tests were performed during follow-up to confirm progressive lung enhancement.
Conclusion: The use of nintedanib seems to have minimized the lung injury induced by COVID-19 after continuous follow-up for a period of 9 months both clinically and radiologically with improvement in lung function.
Coronavirus disease; Pulmonary fibrosis; Severe acute respiratory syndrome
Anusmriti Pal, Anand K Mishra, Manoj K Yadav, Rajendra Mani Giri, Khadga B Shah.Use of Nintedanib and its Outcome among Post-COVID Pulmonary Fibrosis Patients Residing at High Altitudes: A Case Series. Int Clinc Med Case Rep Jour. 2023;2(18):1-6.